The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026

Abstract

Survival in metastatic pancreatic ductal adenocarcinoma (mPDAC) has long been limited by a dismal second-line therapeutic ceiling dictated by conventional chemotherapy. However, breakthrough data from the ASCO 2026 Annual Meeting and the publication of the phase III RASolute-302 trial mark a definitive shift toward targeted KRAS inhibition. This correspondence highlights how the first-in-class pan-RAS (ON) inhibitor daraxonrasib (RMC-6236) virtually doubled median overall survival (13.2 vs. 6.6 months) and progression-free survival compared to chemotherapy in second-line mPDAC, establishing a new standard of care. Concurrently, we evaluate emerging allele-specific strategies from ASCO 2026 designed to optimize target engagement and safety. These include the selective KRAS G12D inhibitor DN022150 and promising horizontal combinations pairing the G12D inhibitor HRS-4642 with either the anti-PD-L1 antibody adebrelimab or a Nectin-4-targeted antibody-drug conjugate (ADC). Furthermore, we address the KRAS G12C cohort where farnesyl transferase co-inhibition (darlifarnib plus adagrasib) successfully bypasses adaptive resistance. Ultimately, the therapeutic landscape of mPDAC is transitioning toward tailored genomic frameworks. Future success will rely on optimizing the clinical sequencing or combination of pan-RAS and allele-specific agents, guided by real-time liquid biopsies, to permanently dismantle resistance and transform mPDAC into a manageable molecular entity.

To the Editor:

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is associated with one of the worst prognoses among solid tumors and remains a major therapeutic challenge [1, 2]. Driven by oncogenic KRAS mutations in over 90% of cases, this tumor has long been deemed “undruggable” due to high heterogeneity of specific mutant alleles, alternative signaling escape pathways, and a notoriously hostile, desmoplastic microenvironment [3–5]. For decades, the second-line therapeutic ceiling has been firmly dictated by conventional one-size-fits-all chemotherapy, yielding a dismal prognosis, with median overall survival (OS) ranging from 4 to 6 months, median progression-free survival (PFS) of 3–4 months, and an overall response rate (ORR) of around 10% [6]. However, the recent presentation at the ASCO 2026 Annual Meeting and the concurrent publication of the landmark phase III RASolute-302 trial [7] mark a definitive paradigm shift, supporting targeted (K)RAS inhibition as a new standard of care.

The RASolute-302 Benchmark and Pan-RAS efficacy

The global, randomized phase III RASolute-302 trial evaluated daraxonrasib (RMC-6236), a first-in-class, oral, RAS (ON) multi-selective inhibitor, versus investigator’s choice of standard chemotherapy in 500 patients in second-line mPDAC [7]. Daraxonrasib binds cyclophilin A and consequently blocks the active, GTP-bound state of both wild-type and mutant RAS proteins disrupting the signaling cascade. The trial achieved unprecedented results in both the RAS G12 and the overall populations. In patients harboring RAS G12 mutations, daraxonrasib virtually doubled median OS to 13.2 months compared to 6.6 months in the chemotherapy arm (HR 0.40, 95% CI 0.30–0.54; p < 0.001). PFS was similarly doubled (7.3 vs. 3.5 months; HR 0.45; 95% CI 0.34–0.59; p < 0.001), accompanied by a tripling of the ORR, 33.2% (95% CI, 27.0–39.9) with daraxonrasib vs. 11.8% (95% CI 7.8–16.8; p < 0.001) with chemotherapy. In the overall population, outcomes with daraxonrasib and chemotherapy closely reflected those in the RAS G12 population (Table 1), establishing daraxonrasib as the new second-line standard of care. Daily oral administration offered a favorable safety profile, leading to a remarkably low discontinuation rate due to toxicities (1.2%) (Table 1). With a median dose intensity of 93.1%, dose reductions and interruptions occurred in 36.1% and 56.8%, respectively. The most commonly reported G3-4 treatment-related adverse events (TRAEs) were skin rash (14%), stomatitis (12%), and diarrhea (5%). This landmark trial demonstrates that broad-spectrum inhibition of the active state of RAS can successfully bypass the traditional structural and adaptive resistance of PDAC.

Table 1.

Clinical Efficacy of the Landmark Phase III RASolute-302 Trial

RAS G12 population
Parameter	Daraxonrasib (RMC-6236) Arm (n=228)	Standard Chemotherapy Arm (n=231)	Hazard Ratio (HR) / p-value
Median Overall Survival (OS)	13.2 months	6.6 months	HR = 0.40 (95% CI 0.30-0-54) p<0.001
Median Progression-Free Survival (PFS)	7.3 months	3.5 months	HR = 0.45 (95% CI 0.34-0-59) p<0.001
Objective Response Rate (ORR)	33.2% (95% CI, 27.0-39.9)	11.8% (95% CI, 7.8-16.8)	p<0.001

Overall population
Parameter	Daraxonrasib (RMC-6236) Arm (N=248)	Standard Chemotherapy Arm (N=252)	Hazard Ratio (HR) / p-value
Median Overall Survival (OS)	13.2 months	6.7 months	HR = 0.40 (95% CI 0.30-0-53) p<0.001
Median Progression-Free Survival (PFS)	7.2 months	3.6 months	HR = 0.49 (95% CI 0.38-0-64) p<0.001
Objective Response Rate (ORR)	31.6% (95% CI, 25.8-38.0)	11.2% (95% CI, 7.5-15.9)	p<0.001

Emerging allele-specific regimens and future horizons

While pan-RAS inhibitors like daraxonrasib offer a broad-spectrum approach that prevents upstream adaptive feedback loops at the cost of a narrower therapeutic window due to wild-type inhibition, allele-specific strategies maximize tolerability by sparing healthy tissues, though they actively require synergistic combination partners to overcome bypassed escape pathways [8] (Table 2). Data presented at the ASCO 2026 Annual Meeting provide further support for this approach. In the KRAS G12D landscape, the novel selective noncovalent small-molecule inhibitor DN022150 demonstrated potent antitumor activity in a phase I/IIa study in 56 patients with locally advanced or metastatic solid tumors (of which 66.1% were pancreatic cancers), where 96.8% of patients achieved target lesion reduction, with an ORR up to 37.5% at 450 mg. To maximize G12D target engagement, vertical and horizontal co-inhibition strategies have emerged. The phase I/II study of the high-affinity KRAS G12D inhibitor HRS-4642 combined with the anti-PD-L1 antibody adebrelimab yielded a remarkable confirmed ORR of 48.5% and a median OS of 11.5 months in pretreated mPDAC, showcasing the potential to reverse the immunosuppressive tumor microenvironment [9, 10]. Concurrently, pairing HRS-4642 with SHR-A2102, a novel Nectin-4-targeted antibody-drug conjugate (ADC), demonstrated a tolerable safety window and encouraging preliminary efficacy (ORR 36.7%, median PFS 4.1 months) [11]. Finally, addressing the KRAS G12C cohort, the FIT-001 trial explored the farnesyl transferase inhibitor darlifarnib combined with adagrasib to bypass adaptive resistance mediated by persistent mTORC1 signaling, achieving an impressive 60% ORR and 100% disease control rate (DCR) within the mPDAC cohort (n = 5) [12].

Table 2.

Landscape of Emerging Allele-Specific Targeted Regimens for Mutant mPDAC at ASCO 2026

Study/Abstract	Target/Population	Experimental Regimen	Key Clinical/Safety Findings
Abstract #3007	KRAS G12D Advanced solid tumors (66.1% pancreatic)	DN022150 (Selective noncovalent inhibitor)	96.8% of patients with target lesion reduction; ORR of 31.3%–37.5%. Main TRAEs: G3 neutropenia, anemia.
Abstract #4190	KRAS G12D Pretreated mPDAC (n = 33 RP2D)	HRS-4642 + Adebrelimab (Anti-PD-L1)	Confirmed ORR of 48.5%, DCR 90.9%, and median OS of 11.5 months. Main G3/4 TRAEs: elevated lipase/GGT.
Abstract #4191	KRAS G12D Pretreated mPDAC (n = 30 RED)	HRS-4642 + SHR-A2102 (Anti-Nectin-4 ADC)	Confirmed ORR of 36.7%, DCR 86.7%, and median PFS of 4.1 months. Manageable safety profile.
Abstract #3078	KRAS G12C Heavily pretreated solid tumors (20% PDAC)	Darlifarnib (FTI) + Adagrasib (KRAS G12Ci)	mPDAC cohort (n = 5) achieved 60% ORR and 100% DCR. Manages mTORC1-mediated resistance.

Looking ahead, the future of mPDAC therapeutics lies in optimizing the clinical sequencing or combination between pan-RAS and allele-specific agents, particularly in light of potential resistance mechanisms, alongside moving these targeted frameworks into early disease settings. Transitioning from monotherapy to tailored horizontal combinations, incorporating immune checkpoint inhibitors, novel ADCs, or downstream pathway blockers, guided by real-time liquid biopsy monitoring of clonal evolution, represents the next frontier to permanently dismantle adaptive resistance and transform mPDAC from a historically lethal disease into a manageable molecular entity.

Author contributions

SP conceived the study and drafted the initial manuscript. EG, MB, AG, DL, DR collected and analyzed the data from the ASCO 2026 abstracts and designed the tables. GP designed the tables and revised the manuscript. DL, DR, EG revised the manuscript. LA critically revised the manuscript for important intellectual content and supervised the project. All authors read and approved the final manuscript.

Funding

Not applicable.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

DR: speakers’ Bureau: Amgen, Pierre Fabre, Bayer, Takeda, MSD, Merck; travel: Merck. EG: Abbvie, Servier, Gentili; travel: Ipsen. DL: advisory: Daiichi Sankyo, MSD, Amgen, Servier; travel: Servier, Merck, Amgen, Pfizer. LA: payment or honoraria for lectures and presentation: ASTRA ZENECA, ROCHE, ASTELLAS, NOVARTIS, MSD, BMS, IPSEN, MERK SERONO, AMGEN, BAYER; support for attending meeting and/or travel grant: ASTRA ZENECA, NOVARTIS, IPSEN, MERK SERONO, AMGEN, SERVIER; advisory Board: Abbott, Pharmacosmos, BMS. GP, AG, SP and MB have no competing interest.